Psycho-Babble Medication Thread 1098514

Shown: posts 1 to 4 of 4. This is the beginning of the thread.

 

Trintellix Label Updated: Improved Processing Spee

Posted by PeterMartin on May 4, 2018, at 7:53:00

Mey 3, 2018

Trintellix Labeling Updated With Data on Improved Processing Speed in MDD

https://www.empr.com/news/trintellix-vortioxetine-major-depressive-disorder-processing-speed-cognitive-function/article/763209/

Lundbeck announced that the Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Trintellix (vortioxetine) to include data regarding improved processing speed, an important aspect of cognitive function that may be impaired in patients with major depressive disorder (MDD).

The approval was based on data from the 8-week, randomized, double-blind, placebo-controlled studies, FOCUS and CONNECT, which investigated the effect of Trintellix on various aspects of cognitive function among adults aged 18 to 65 years with depression. Study patients were given Trintellix 10mg, 20mg or placebo daily and assessed via the Digit Symbol Substitution Test (DSST), a neuropsychological measure that evaluates processing speed.

In both studies, patients treated with Trintellix had a statistically significantly greater improvement in the number of correct responses on the DSST vs placebo. In addition, depressed mood as assessed by change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score also improved in both studies. The positive effects seen on the DSST may reflect improvement in depression.

Trintellix, a serotonergic agonist and antagonist, was approved by the FDA in September 2013 for the treatment of adults with MDD. Its mechanism is thought to be related to the enhancement of serotonergic activity in the central nervous system (CNS) through inhibition of serotonin reuptake.

 

Re: Trintellix Label Updated: Improved Processing Spee PeterMartin

Posted by SLS on May 5, 2018, at 19:04:45

In reply to Trintellix Label Updated: Improved Processing Spee, posted by PeterMartin on May 4, 2018, at 7:53:00

Thanks for posting this.


- Scott

 

Re: Trintellix Label Updated: Improved Processing Spee PeterMartin

Posted by beckett2 on May 6, 2018, at 0:16:17

In reply to Trintellix Label Updated: Improved Processing Spee, posted by PeterMartin on May 4, 2018, at 7:53:00

> Mey 3, 2018
>
> Trintellix Labeling Updated With Data on Improved Processing Speed in MDD
>
> https://www.empr.com/news/trintellix-vortioxetine-major-depressive-disorder-processing-speed-cognitive-function/article/763209/
>
> Lundbeck announced that the Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Trintellix (vortioxetine) to include data regarding improved processing speed, an important aspect of cognitive function that may be impaired in patients with major depressive disorder (MDD).
>
> The approval was based on data from the 8-week, randomized, double-blind, placebo-controlled studies, FOCUS and CONNECT, which investigated the effect of Trintellix on various aspects of cognitive function among adults aged 18 to 65 years with depression. Study patients were given Trintellix 10mg, 20mg or placebo daily and assessed via the Digit Symbol Substitution Test (DSST), a neuropsychological measure that evaluates processing speed.
>
> In both studies, patients treated with Trintellix had a statistically significantly greater improvement in the number of correct responses on the DSST vs placebo. In addition, depressed mood as assessed by change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score also improved in both studies. The positive effects seen on the DSST may reflect improvement in depression.
>
> Trintellix, a serotonergic agonist and antagonist, was approved by the FDA in September 2013 for the treatment of adults with MDD. Its mechanism is thought to be related to the enhancement of serotonergic activity in the central nervous system (CNS) through inhibition of serotonin reuptake.
>

I'm doing well on Trintellix. After at least two years, I might be finding a higher plateau. Maybe that doesn't make sense. So far, this is the best recovery I've experienced since my life went to sh*t 14 years ago. Trintellix + lamictal.

 

Re: Trintellix Label Updated: Improved Processing Spee PeterMartin

Posted by beckett2 on May 6, 2018, at 0:20:35

In reply to Trintellix Label Updated: Improved Processing Spee, posted by PeterMartin on May 4, 2018, at 7:53:00

> Mey 3, 2018
>
> Trintellix Labeling Updated With Data on Improved Processing Speed in MDD
>
> https://www.empr.com/news/trintellix-vortioxetine-major-depressive-disorder-processing-speed-cognitive-function/article/763209/
>
> Lundbeck announced that the Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Trintellix (vortioxetine) to include data regarding improved processing speed, an important aspect of cognitive function that may be impaired in patients with major depressive disorder (MDD).
>
> The approval was based on data from the 8-week, randomized, double-blind, placebo-controlled studies, FOCUS and CONNECT, which investigated the effect of Trintellix on various aspects of cognitive function among adults aged 18 to 65 years with depression. Study patients were given Trintellix 10mg, 20mg or placebo daily and assessed via the Digit Symbol Substitution Test (DSST), a neuropsychological measure that evaluates processing speed.
>
> In both studies, patients treated with Trintellix had a statistically significantly greater improvement in the number of correct responses on the DSST vs placebo. In addition, depressed mood as assessed by change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score also improved in both studies. The positive effects seen on the DSST may reflect improvement in depression.
>
> Trintellix, a serotonergic agonist and antagonist, was approved by the FDA in September 2013 for the treatment of adults with MDD. Its mechanism is thought to be related to the enhancement of serotonergic activity in the central nervous system (CNS) through inhibition of serotonin reuptake.
>

P.S. I appreciate your posts and links :)


This is the end of the thread.


Show another thread

URL of post in thread:


Psycho-Babble Medication | Extras | FAQ


[dr. bob] Dr. Bob is Robert Hsiung, MD, bob@dr-bob.org

Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.